286 related articles for article (PubMed ID: 28654655)
21. Stage T1N0M0 renal cell carcinoma: the prognosis in Asian patients.
Zhang ZL; Chen W; Li YH; Liu ZW; Luo JH; Lau W; Tan MH; Zhou FJ
Chin J Cancer; 2011 Nov; 30(11):772-8. PubMed ID: 22035858
[TBL] [Abstract][Full Text] [Related]
22. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
[TBL] [Abstract][Full Text] [Related]
23. Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy.
Lau WK; Cheville JC; Blute ML; Weaver AL; Zincke H
Urology; 2002 Apr; 59(4):532-7. PubMed ID: 11927308
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
25. Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma.
Gayed BA; Youssef RF; Bagrodia A; Darwish OM; Kapur P; Sagalowsky A; Lotan Y; Margulis V
BJU Int; 2014 Apr; 113(4):668-73. PubMed ID: 23937277
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of clinical and pathological factors for surgically treated localized clear cell renal cell carcinoma.
Teng J; Gao Y; Chen M; Wang K; Cui X; Liu Y; Xu D
Chin Med J (Engl); 2014; 127(9):1640-4. PubMed ID: 24791867
[TBL] [Abstract][Full Text] [Related]
27. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
28. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.
Dornbusch J; Zacharis A; Meinhardt M; Erdmann K; Wolff I; Froehner M; Wirth MP; Zastrow S; Fuessel S
PLoS One; 2013; 8(9):e76386. PubMed ID: 24086736
[TBL] [Abstract][Full Text] [Related]
29. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
[TBL] [Abstract][Full Text] [Related]
30. Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression.
Abel EJ; Bauman TM; Weiker M; Shi F; Downs TM; Jarrard DF; Huang W
Hum Pathol; 2014 May; 45(5):1092-9. PubMed ID: 24746216
[TBL] [Abstract][Full Text] [Related]
31. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Laba P; Wang J; Zhang J
BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
[TBL] [Abstract][Full Text] [Related]
32. NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy.
Liang ZL; Kang K; Yoon S; Huang SM; Lim JS; Kim JM; Lim JS; Lee HJ
Ann Surg Oncol; 2012 Aug; 19(8):2763-72. PubMed ID: 22246425
[TBL] [Abstract][Full Text] [Related]
33. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma.
Sandlund J; Oosterwijk E; Grankvist K; Oosterwijk-Wakka J; Ljungberg B; Rasmuson T
BJU Int; 2007 Sep; 100(3):556-60. PubMed ID: 17608827
[TBL] [Abstract][Full Text] [Related]
35. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
[TBL] [Abstract][Full Text] [Related]
36. Tumour immune microenvironment in primary and metastatic papillary renal cell carcinoma.
Eich ML; Chaux A; Mendoza Rodriguez MA; Guner G; Taheri D; Rodriguez Pena MDC; Sharma R; Allaf ME; Netto GJ
Histopathology; 2020 Feb; 76(3):423-432. PubMed ID: 31494951
[TBL] [Abstract][Full Text] [Related]
37. PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.
Högner A; Krause H; Jandrig B; Kasim M; Fuller TF; Schostak M; Erbersdobler A; Patzak A; Kilic E
Urol Oncol; 2018 Mar; 36(3):94.e1-94.e14. PubMed ID: 29169846
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
[TBL] [Abstract][Full Text] [Related]
39. BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma.
Kapur P; Christie A; Raman JD; Then MT; Nuhn P; Buchner A; Bastian P; Seitz C; Shariat SF; Bensalah K; Rioux-Leclercq N; Xie XJ; Lotan Y; Margulis V; Brugarolas J
J Urol; 2014 Mar; 191(3):603-10. PubMed ID: 24076305
[TBL] [Abstract][Full Text] [Related]
40. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
